Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fosfomycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosfomycin SCHEMBL9634052 | 1.00 | LMNA (0.48) | LMNAMAPTBLMPMP22CYP2C9 | |
| Fosfomycin SCHEMBL1442686 | 1.00 | — | — | |
| Fosfomycin SCHEMBL3168929 | 0.97 | — | — | |
| Fosfomycin SCHEMBL8633252 | 0.97 | — | — | |
| Fosfomycin SCHEMBL3168937 | 0.97 | — | — | |
| Fosfomycin SCHEMBL9634477 | 0.97 | — | — | |
| Fosfomycin SCHEMBL10492648 | 0.97 | — | — | |
| Fosfomycin SCHEMBL989825 | 0.97 | — | — | |
| Fosfomycin SCHEMBL5595663 | 0.97 | LMNA (0.50) | LMNAMAPTBLMPMP22CYP2C9 | |
| Fosfomycin SCHEMBL50951 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12480920-B2 | Method for the detection and quantification of fosfomycin, impurities and degradation products thereof | MEITHEAL PHARMACEUTICALS, INC. (US) | 2025-11-25 | — | — | US | claimed |
| WO-2024147727-A1 | SYNTHESIS OF FOSFOMYCIN DISODIUM | INTERQUIM S.A. DE C.V. (MX) | 2024-07-11 | — | — | WO | claimed |
| EP-4353323-A2 | COMPOSITIONS FOR ELIMINATING BACTERIAL PROMOTORS OF A COLORECTAL TUMOR BY INTRALUMINAL APPLICATION | Reponex Pharmaceuticals A/S (DK) | 2024-04-17 | — | — | EP | claimed |
| EP-3740286-B1 | COMPOSITIONS FOR ELIMINATING BACTERIAL PROMOTORS OF COLORECTAL CANCER BY INTRALUMINAL APPLICATION | REPONEX PHARMACEUTICALS AS (DK) | 2024-02-07 | — | — | EP | claimed |
| EP-4268805-A1 | FOSFOMYCIN FORMULATION FOR PARENTERAL ADMINISTRATION AND METHOD OF MANUFACTURING SAME | Georgopoulos, Apostolos (AT) | 2023-11-01 | — | — | EP | claimed |
| CN-116683025-A | Positive electrode sodium supplement additive and sodium ion battery | 天津中电新能源研究院有限公司 | 2023-09-01 | — | — | CN | claimed |
| US-20220146470-A1 | METHOD FOR THE DETECTION AND QUANTIFICATION OF FOSMOMYCIN, IMPURITIES AND DEGRADATION PRODUCTS THEREOF | MEITHEAL PHARMACEUTICALS, INC. | 2022-05-12 | — | — | US | claimed |
| US-10993951-B2 | Fosfomycin formulation for parenteral administration | GEORGOPOULOS APOSTOLOS (AT) | 2021-05-04 | — | — | US | claimed |
| US-20210060038-A1 | COMPOSITIONS FOR ELIMINATING BACTERIAL PROMOTORS OF COLORECTAL CANCER BY INTRALUMINAL APPLICATION | Reponex Pharmaceuticals A/S (DK) | 2021-03-04 | — | — | US | claimed |
| EP-3740286-A1 | COMPOSITIONS FOR ELIMINATING BACTERIAL PROMOTORS OF COLORECTAL CANCER BY INTRALUMINAL APPLICATION | Reponex Pharmaceuticals A/S (DK) | 2020-11-25 | — | — | EP | claimed |
| US-20130303476-A1 | Aminoglycoside and Fosfomycin Combination for Treatment of Ventilator Associated Pneumonia (VAP) and Ventilator Associated Tracheal (VAT) Bronchitis | SAVARA INC. | 2013-11-14 | — | — | US | claimed |
| US-20130014759-A1 | FORMULATIONS OF AMINOGLYCOSIDE AND FOSFOMYCIN COMBINATIONS AND METHODS AND SYSTEMS FOR TREATMENT OF VENTILATOR ASSOCIATED PNEUMONIA (VAP) AND VENTILATOR ASSOCIATED TRACHEAL (VAT) BRONCHITIS | Cardeas Pharma Inc. | 2013-01-17 | — | — | US | claimed |
| WO-2013010041-A1 | FORMULATIONS OF AMIKACIN AND FOSFOMYCIN COMBINATIONS AND METHODS AND SYSTEMS FOR TREATMENT OF VENTILATOR ASSOCIATED PNEUMONIA (VAP) AND VENTILATOR ASSOCIATED TRACHEAL (VAT) BRONCHITIS | Cardeas Pharma Inc. (US) | 2013-01-17 | — | — | WO | claimed |
| WO-2012154483-A1 | DRY POWDER FOSFOMYCIN/TOBRAMYCIN FORMULATION FOR INHALATION | GILEAD SCIENCES, INC. (US) | 2012-11-15 | — | — | WO | claimed |
| CN-102112125-A | Antibacterial combination therapy for the treatment of gram positive bacterial infections | E THERAPEUTICS PLC | 2011-06-29 | — | — | CN | claimed |
| EP-2328573-A1 | ANTIBACTERIAL COMBINATION THERAPY FOR THE TREATMENT OF GRAM POSITIVE BACTERIAL INFECTIONS | E-Therapeutics plc (GB) | 2011-06-08 | — | — | EP | claimed |
| WO-2010007381-A1 | ANTIBACTERIAL COMBINATION THERAPY FOR THE TREATMENT OF GRAM POSITIVE BACTERIAL INFECTIONS | E-THERAPEUTICS PLC (GB) | 2010-01-21 | — | — | WO | claimed |
| EP-1762573-A1 | A process for the preparation of fosfomycin salts | Interquim, S.A. De C.V. (MX) | 2007-03-14 | — | — | EP | claimed |
| US-6413946-B1 | USING FOSFOMYCIN AND VANADIUM COMPOUND | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-07-02 | — | — | US | claimed |
| EP-1033133-A1 | COMPOSITION FOR TREATMENT OF DIABETES AND TREATMENT OF DIABETES | Meiji Seika Kaisha, Ltd. (JP) | 2000-09-06 | — | — | EP | claimed |